Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POSIT: Neoadjuvant Serplulimab + SOX +/- Radiotherapy for Gastric/GEJ Adenocarcinoma
NCT07674342Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Randomised, open-label trial of serplulimab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Tongji Hospital. Primary endpoint: Pathological Complete Response. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
serplulimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07674342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07674342.